A selective agonist radioligand for A 2B adenosine receptors (A 2B ARs) is currently not available. Such a tool would be useful for labeling the active conformation of the receptors. Therefore, we prepared BAY 60-6583, a potent and functionally selective A 2B AR (partial) agonist, in a tritium-labeled form. Despite extensive efforts, however, we have not been able to establish a radioligand binding assay using [ 3 H]BAY 60-6583. This is probably due to its high non-specific binding and its moderate affinity, which had previously been overestimated based on functional data. As an alternative, we evaluated the non-selective A 2B 
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Introduction
The G protein-coupled adenosine receptors (ARs) are divided into four subtypes: A 1 , A 2A , A 2B , and A 3 . While A 1 and A 3 ARs are coupled to G i proteins mediating an inhibition of adenylate cyclase, A 2A and A 2B ARs are coupled to G s proteins resulting in a stimulation of the enzyme [1] . The A 2B ARs can additionally couple to G q proteins resulting in phospholipase C activation followed by intracellular calcium release [2] . Depending on the structure of agonists and antagonists, different receptor conformations may be induced and stabilized potentially leading to functional selectivity with regard to different signaling pathways, e.g., G protein activation versus β-arrestin recruitment [3] . GPCRs can also form homo-or heteromeric di-or oligomers [4] which may display an altered pharmacology [5, 6] . ARs are involved in a range of diseases including cardiovascular, nervous system, pulmonary, and kidney disorders, and adenosine mediates various effects including anti-inflammatory and immune-suppressive activity [7] . Therefore, ARs represent therapeutic drug targets, and the development of selective agonists and antagonists for medical applications has been of great interest. The A 2A and A 2B AR subtypes have recently become major targets in immuno-oncological drug development [8] . The wellinvestigated A 2A AR subtype is typically activated by relatively low nanomolar concentrations of adenosine, whereas the A 2B AR subtype requires higher micromolar adenosine concentrations for activation. Only few selective A 2B AR agonists have been described, the most prominent one being the nonnucleosidic partial agonist 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl]acetamide (BAY 60-6583) [9, 10] . Only very few other potent A 2B AR agonists, all derived from the nucleoside adenosine, have been reported, mainly by the group of Baraldi's [11] [12] [13] , but their degree of selectivity is unclear since A 2B AR data obtained in cAMP accumulation assays were compared to A 1 , A 2A , and A 3 AR radioligand binding data. However, functional assays are highly dependent on receptor expression levels and receptor reserve [14] . In contrast to the situation with agonists, many potent and selective A 2B AR antagonists have been developed [13, [15] [16] [17] [18] [19] [20] [21] and evaluated in preclinical and initial clinical trials [22] . PSB-603 is one of the most potent and selective A 2B antagonists, which is frequently used as a tool compound to study A 2B ARs [23] [24] [25] [26] . In Fig. 1 , a selection of important non-selective and selective A 2B AR agonists and antagonists is depicted including NECA, CADO, BAY 60-6583, caffeine, PSB-603, and CGS-15943. Radioligand receptor binding is a powerful method for the screening of new potential ligands, and the obtained data provide an ideal basis for structure-activity relationship analyses. Agonist radioligands label an active receptor conformation which displays high affinity for agonists while neutral antagonist radioligands bind to active and inactive receptor conformations with similar affinity. Inverse agonist radioligands label an inactive receptor conformation, for which agonists typically display low affinity [27] . For competition binding assays, agonist or antagonist radioligands can be employed, both of which will provide different information about a test compound. While agonists typically show higher affinity when they are tested against agonist radioligands (which label the so-called high-affinity binding site of an active receptor conformation), they usually display lower affinity for an antagonist/ inverse agonist radioligand-labeled, inactive receptor conformation. In some cases, biphasic curves are observed in competition binding assays of agonists versus antagonist radioligands, e.g., for the human A 1 AR [28] . However, at A 2A and A 2B ARs, no biphasic curves have been observed and only inactive, low affinity conformations appeared to be labeled by antagonist radioligands [17, 29] . Consequently, A 2A AR agonists were found to display lower affinity versus antagonist radioligands than versus agonist radioligands. Thus, agonist radioligands are important tools to study the affinity of agonists at A 2A ARs for their high-affinity binding site in the active receptor conformation. Radioligand binding studies have also been crucial for recent X-ray crystallography [30] [31] [32] and NMR studies [33] to prove the correct folding of the receptor proteins after isolation and purification.
Several crystal structures of the human A 2A AR in complex with agonists [34] [35] [36] and antagonists [37] [38] [39] [40] [41] have been published, but the X-ray structure of the A 2B AR has not been resolved so far. Recently, crystal structures of the A 1 AR have been obtained, which provided insights into selectivity among A 1 and A 2A AR subtypes [30, 41] .
For the A 2B AR, potent and selective antagonist radioligands have been developed [15] [16] [17] [18] ; however, no selective A 2B AR agonist radioligand has been described so far. The non-selective AR agonist [ label A 2B ARs [42] [43] [44] [45] . But a systematic characterization of [ 3 H]NECA as a radioligand for A 2B ARs has not been performed, and the radioligand has not been employed for the determination of affinities of series of ligands. The goal of the present study was to establish an agonist radioligand binding assay at human, rat, and mouse A 2B ARs. To this end, our initial strategy was the preparation and utilization of tritiumlabeled BAY 60-6583. However, major difficulties in establishing an A 2B AR binding assay with [ 3 H]BAY 60-6583 promped us to investigate [ 3 H]NECA as an A 2B AR radioligand instead. The radioligand was subsequently used for characterizing the affinities of ligands, in particular agonists, for the high-affinity conformation labeled by the adenosine derivative.
Materials and methods

Materials and (bio)chemicals
[ 3 H]NECA (15.9 Ci/mmol) was supplied by Perkin Elmer Life and Analytical Science (Rodgau-Jügesheim, Germany). All other chemical reagents were purchased from Sigma-Aldrich (Taufkirchen, Germany), Tocris Biosciences (Bristol, UK), or Roth (Karlsruhe, Germany), unless otherwise stated. BAY 60-6583 was synthesized or purchased from Tocris Biosciences (Bristol, UK). All cell culture media and penicillin-streptomycin solutions were obtained from Invitrogen (Darmstadt, Germany). Fetal calf serum (FCS) and G418 were purchased from SigmaAldrich (Taufkirchen, Germany). Cell culture materials (flasks and dishes) were obtained from Labomedic (Bonn, Germany) and Sarstedt (Nümbrecht, Germany), respectively.
Retroviral transfection of GP
+ env AM12 cells and infection of CHO-K1 cells CHO cells stably expressing human, rat, or mouse A 2B ARs were generated using a retroviral expression system as previously described [46] .
Cell culture
CHO cells stably transfected with the human, rat, or mouse A 2B AR were maintained in DMEM-F12 medium with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.8 mg/ml G418 at 37°C and 5% CO 2 .
Membrane preparations
Membranes of CHO cells stably expressing human, rat, or mouse A 2B ARs were prepared as previously described [16, 46] . Membranes from HEK-hA 2B cells which were used for some of the competition binding studies were purchased from Perkin Elmer (Rodgau-Jügesheim, Germany).
Radioligand receptor binding studies
The radiosynthesis was performed starting from an iodinesubstituted precursor in a single step by iodine-tritium exchange catalyzed by palladium black in tetrahydrofurane in the presence of triethylamine as a base. The product was purified and analyzed by RP-HPLC using the following conditions: column: Phenomenex AQUA C18, 5 μm, mobile phase: acetonitrile:water (1:1), flow rate of 1 and 5 ml/min, respectively. The analytical HPLC chromatogram with radio Fig. 1 Structures of the the nonselective AR agonist NECA (1), the non-selective AR agonist CADO (2), the selective (partial) A 2B AR agonist BAY 60-6583 (3), the non-selective AR antagonist caffeine (4), the selective A 2B AR antagonist PSB-603 (5), and the non-selective AR antagonist CGS-15943 (6) detection and UV detection (254 nm) showed high purity of the product [ 
Binding experiments with [ 3 H]BAY 60-6583
Initial binding experiments with [ 3 H]BAY 60-6583 were performed in a final assay volume of 0.5 ml containing test compound dissolved in DMSO (25 μl), 275 μl of assay buffer (50 mM Tris-HCl, pH 7.4), 100 μl of radioligand solution (1 nM) in assay buffer, and 100 μl of human A 2B AR membrane preparation (30 μg per vial) suspended in assay buffer containing adenosine deaminase (ADA; 2 U/mg protein, 20 min preincubation at rt). Non-specific binding was determined in the presence of 1 mM NECA, 10 μM DPCPX, or 10 μM PSB-1115, respectively. After an incubation time of 30 min at rt, the assay mixture was rapidly filtered through GF/B glass fiber filters using a 24-well Brandel harvester (Brandel, Gaithersburg, MD). Filters were washed three times (3 ml each) with ice-cold 50 mM Tris-HCl buffer, pH 7.4. Then filters were transferred to vials, incubated for 9 h with 2.5 ml of scintillation cocktail (LumaSafe plus, Perkin-Elmer), and counted in a liquid scintillation counter (Tricarb 2700TR) with a counting efficiency of 53%. For additional experiments, a final volume of 0.5 ml, 2.5% DMSO, GF/C filters, higher radioligand concentrations (5, 10, 20 nM), and MgCl 2 (3 mM) in the incubation buffer were employed. Additionally, the A 2B AR amount was increased to 80 μg of membrane preparation per vial, and the incubation time was increased to 140 min at rt. Further experiments were conducted at 4°C.
Competition binding experiments with [ Non-specific binding was determined in the presence of 250 μM NECA. After an incubation time of 4 h at 4°C, the assay mixture was rapidly filtered through GF/C glass fiber filters using a 24-well Brandel harvester (Brandel, Gaithersburg, MD). Filters were washed four times (3 ml each) with ice-cold 50 mM Tris-HCl buffer, pH 7.4. Then filters were transferred to scintillation vials, incubated for 9 h with 2.5 ml of scintillation cocktail (LumaSafe plus, Perkin-Elmer), and counted in a liquid scintillation counter (Tricarb 2700TR) with a counting efficiency of 53%.
Kinetic experiments with [ 3 H]NECA
Association experiments were performed at 4°C with eight different time points and over a time period of 240 min. Dissociation experiments were initiated after 240 min of preincubation by the addition of 250 μM NECA. Three separate experiments were performed, each in duplicates. All other conditions were as described above for competition binding experiments.
Saturation binding experiments with [ 3 H]NECA
Saturation experiments at recombinant human and rat A 2B ARs were conducted to determine the K D values for the radiolabeled agonist NECA at the different species. Different amounts of membrane preparation per vial, which were dependent on the receptor expression (200 μg for human and 250 μg for rat), and 7-9 different concentrations of 
Data analysis
All data were analyzed using Graph Pad Prism, version 4.0 (San Diego, CA, USA). K D values from homologous competition binding experiments were calculated according to the Cheng and Prusoff equation [47] . In homologous competition binding experiments, radioligand and competitor are the same; therefore, K D is equal to K i , and the Cheng and Prussoff equation can be simplified to K D = IC 50 − [radioligand].
Results
Attempts to establish an A 2B AR binding assay with [
H]BAY 60-6583
The initial goal of the present study was to establish a radioligand binding assay using the A 2B AR agonist Supplemental Fig. 4 ). For subsequent experiments, a final volume of 0.5 ml, 2.5% DMSO, GF/C filters, higher radioligand concentrations (5, 10, 20 nM), and the addition of MgCl 2 (3 mM) to the incubation buffer were tested. Mg 2+ may shift the A 2B AR to an active conformation to which agonists show high affinity as observed for the A 2A AR [48] . Under these conditions and with 5 nM of [ 3 H]BAY 60-6583, an increased degree of specific binding of 30-40% could be achieved (Fig. 2) . With higher radioligand concentrations, non-specific binding was much higher as could be expected. The moderate specific binding of [ 3 H]BAY 60-6583 was too low to establish a reliable radioligand binding assay, which would require at least 50%, preferably 70% of specific binding. Therefore, different washing buffers were tested. But non-specific binding could not be further reduced, neither by the addition of 5% DMSO nor by adding 5% ethanol to the washing buffer. Many further modifications were tried, including preincubation of the filters in 1% aqueous polyethylenimine solution for 30 
Kinetic experiments
Due to the expected moderate affinity at the human A 2B AR and fast dissociation of NECA from the A 2B AR, kinetic experiments were performed at 4°C using 30 nM of [ 3 H]NECA, which gave sufficiently high specific binding (see below). All experiments were best fitted using a single binding site model (Fig. 3a, b) . Association (Fig. 3a) reached equilibrium within less than 30 min with a t 1/2 of 9.7 ± 1.0 min. Equilibrium binding was stable for at least 240 min. After the addition of a high concentration of unlabeled NECA (250 μM), [ 3 H]NECA binding was rapidly reversed as shown in Fig. 3b . Because the dissociation (t 1/2 = 0.4 ± 0.1 min) was very fast, much faster than the association, it was not possible to calculate a kinetic K D value from the k on and k off values.
Next we performed saturation binding experiments to determine K D and B max values.
Saturation experiments
Saturation binding experiments were carried out using [ 3 H]NECA on membrane preparations recombinantly expressing A 2B ARs of different species, human and rat. H]NECA binding was saturable, and the obtained data were in all cases best fitted to a monophasic curve. For the human A 2B AR, a K D value of 441 ± 169 nM and a B max value of 2150 ± 449 fmol/mg protein were determined (Fig. 4a) (Fig. 4b) . Again, the determined K D value was about 3-fold lower than the K i value determined for NECA in competition binding assays versus the antagonist radioligand [ 3 H]PSB-603 at rat A 2B ARs (1110 nM) [46] .
Competition binding experiments
Next, we performed homologous competition binding experiments measuring concentration-dependent inhibition of unlabeled NECA versus [ (Fig. 5a ), 532 ± 65 nM and 4400 ± 1500 fmol/mg protein for rat A 2B ARs, and 465 ± 104 nM and 1480 ± 451 fmol/mg for mouse A 2B ARs (Fig. 5b) . The competition binding assay conditions were subsequently used for the determination of the affinities of a structurally diverse set of A 2B AR ligands, agonists, and antagonists.
For agonists determined versus the agonist radioligand Table 1 ).
For 2-chloroadenosine (CADO), a monophasic curve was obtained (Fig. 5c) Fig. 5a, b, c) (Fig. 7) . Likewise, the K i value determined for PSB-603 at human A 2B ARs was significantly (4-fold) higher when determined versus [ (Fig. 7) . The largest difference was observed for the adenine-like antagonist CGS-15943 (12-fold difference). All three investigated antagonists were not able to fully block [ 3 H]NECA at human, mouse, and rat A 2B ARs. The curves were best fitted by monophasic isotherms. At human A 2B ARs, a K i value of 31,400 ± 7750 nM, at mouse A 2B AR, a K i value of 10,300 ± 3400 nM, and at rat A 2B AR, a K i value of 10,400 ± 3430 nM were determined. In all experiments, non-specific binding was determined in the presence of 250 μM NECA. Data points are means ± SEM of two (mouse), three (rat), or five (human) independent experiments performed in duplicates (curves were extrapolated because of low solubility of the compound at concentrations > 30 μM)
Discussion
The initial goal of the present study was to establish a radioligand binding assay with the A 2B AR agonist [ 3 H]BAY 60-6583 as a tool for labeling an active A 2B AR receptor conformation. BAY 60-6583 had previously been reported to display an EC 50 value in the low nanomolar range (3-10 nM) at the human A 2B AR as determined in a gene reporter assay [49] combined with high selectivity versus the other AR subtypes (EC 50 > 10 μM). However, in radioligand binding assays versus the antagonist radioligand [ value of only 114 nM [50] . Functional assays are highly dependent on receptor expression levels and receptor reserve, and are therefore often not comparable with a compound's receptor affinity. Because of major difficulties in establishing an A 2B AR binding assay with [ 3 H]BAY 60-6583 mainly due to its low affinity and high non-specific binding which could not be further reduced with different optimization steps, the compound was not suitable as an agonist radioligand at A 2B ARs (see Fig. 2, Supplemental Figs. 2, 3, 4) .
Therefore, we characterized the binding of the tritiated nonspecific A 2B AR agonist NECA at membrane preparations of CHO or HEK cells stably transfected with human, mouse, or rat A 2B ARs. Kinetic experiments at human A 2B ARs demonstrated that both association and dissociation are monophasic (Fig. 3a, b) . Although the experiments were conducted at 4°C, the association (t 1/2 = 9.7 ± 1.0 min) and in particular the dissociation (t 1/2 = 0.4 ± 0.1 min) were very fast. This relatively fast dissociation is consistent with the moderate affinity of NECA for this receptor subtype. Similarly, fast binding kinetics of [ 3 H]NECA at bovine A 2B ARs were reported by Casado et al. [42] .
Saturation binding experiments at human and rat A 2B ARs were best fitted using a single site binding model (Fig. 4a, b) . The determined K D values of 441 ± 169 nM at human A 2B ARs and 325 ± 144 nM at rat A 2B AR were in the same range as those determined in homologous competition binding experiments (Fig. 5a, b) . For mouse A 2B ARs, a K D value of 465 ± 104 nM was determined in homologous competition binding experiments (Fig. 5b) [16] . In a native cell system, when no agonist is present, there are generally more receptors in the G proteinuncoupled, inactive conformational state than in the G protein-coupled, active state. It is believed that neutral antagonists bind to all affinity states with similar affinity, whereas inverse agonists preferably bind to an inactive receptor state. Full agonists prefer or even shift the equilibrium to an active receptor conformation, which they stabilize [51] . One reason for the higher B max value determined with [ 3 H]NECA is probably the fact that MgCl 2 was included in the agonist assays. Mg 2+ ions increase the coupling of the A 2B ARs to G proteins and therefore promote the active receptor conformation [52] . At A 2A ARs, it was found that MgCl 2 increased agonist radioligand binding, e.g., for [ , and reduced non-specific binding [53] .
In contrast, PSB-603 is an inverse agonist detecting the inactive receptor state. The affinity of the adenosine derivatives NECA and CADO was approximately 3-4-fold higher when tested versus the agonist radioligand than versus 33 ,800 ± 1200 nM for caffeine [16] , 0.553 ± 0.103 nM for PSB-603 [16] , and 30.0 ± 3.9 nM for CGS-15943 [16] . Literature data were from our laboratory performed under the same conditions [16] , 21,400 ± 5700 nM for CADO [16] , and 114 ± 36 nM for BAY 60-6583 [50] . Literature data were from our laboratory performed under the same conditions [ 3 H]PSB-603, which would be expected for agonists. In contrast, the determined A 2B AR affinities for structurally diverse antagonists were higher when tested versus the antagonist as compared to agonist radioligand (Fig. 7 [29] . Also, for the A 1 AR, it was shown that there is a significant rightward shift in agonist binding curves, most pronounced for rat brain A 1 ARs, when using an antagonist radioligand rather than an agonist radioligand (Supplemental Table 2 ), and this discrepancy may be used to functionally characterize A 2A AR ligands for differentiation between agonists and antagonists. For human recombinant A 1 ARs, however, this observation could not be confirmed [54] . It appears that the decrease in affinity may be species or cell context-dependent.
Although BAY 60-6583 is a potent A 2B AR agonist [9] , it showed a large rightward shift in affinity when tested versus the agonist radioligand [ Table 1 ). Thus, BAY 60-6583 behaved like the antagonists, not like the agonists. Because it is structurally very different from adenosine derivatives, which are characterized by a nucleoside structure featuring a ribosyl residue (see Fig. 1 ), the (partial) agonist BAY 60-6583 might stabilize a very different receptor conformation than the full agonist NECA.
Moreover, it was observed that [ Fig. 5a, b, c) . Another more likely explanation would be the presence of a previously described NECA-binding protein designated adenotin [55, 56] . Adenotin, which was later identified as heat shock protein paralog Grp94 [57] , was reported to display submicromolar affinity for NECA and to lack affinity for adenosine receptor antagonists [55, 56] . Saturation analysis with soluble and membrane-derived adenotin had shown a K D value for NECA of 220 nM (soluble) and 210 nM (membranederived) [56] . In a previous study performed in chromaffin plasma cell membranes, the xanthine antagonist DPCPX had shown complete inhibiton of [ 3 H]NECA binding [42] , which might be due to the lack of expression of the NECA-binding protein adenotin in the employed cell line. Binding to nontransfected HEK cell membranes showed some specific binding, which was, however, moderate and may be at least partly due to the endogenous expression of A 2B ARs [58] (see SI Fig. S6 ). In order to avoid effects that are due to binding of ]BAY 60-6583, a potent and functionally selective A 2B AR (partial) agonist, was prepared and examined as a tool for labelling an active A 2B AR conformation. However, despite excessive efforts, we have not been able to establish a radioligand binding assay with this compound mainly due to its high non-specific binding. Nevertheless, [ 3 H]BAY 60-6583 may still be useful for studying in vivo distribution and metabolism of the drug. For the labeling of human, rat, and mouse A 2B ARs, we subsequently investigated binding of the non-selective agonist [ 3 H]NECA as an alternative. This adenosine-like agonist labeled A 2B ARs with an affinity in the higher nanomolar range and showed acceptable nonspecific binding due to its high polarity. [ 3 H]NECA is currently the method of choice for radioligand binding studies aimed at labeling the "high-affinity" active conformation of A 2B ARs. Nevertheless, the development of more potent and selective A 2B AR agonists would be highly desirable. It has to be pointed out that different agonists are most likely binding to and stabilizing different receptor conformations. This was observed in the present study for adenosine derivatives in comparison to the non-nucleoside (partial) agonist BAY 60-6583, an aminopyridine derivative. Moreover, large affinity differences may be measured for compounds dependent on the structure of the radioligand that is used for affinity determination, since each radioligand may label (induce, stabilize) a specific receptor conformation. X-ray structures of the A 2B AR (active conformation) in complex with nucleoside and non-nucleoside agonists would be of great value to further elucidate the receptor's activation mechanisms.
